{{Rsnum
|rsid=3900115
|Gene=CASP10
|Chromosome=2
|position=201185954
|Orientation=plus
|GMAF=0.4027
|Gene_s=CASP10
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 30.1 | 46.9 | 23.0
| HCB | 64.0 | 35.3 | 0.7
| JPT | 76.1 | 21.2 | 2.7
| YRI | 23.1 | 58.5 | 18.4
| ASW | 32.1 | 48.2 | 19.6
| CHB | 64.0 | 35.3 | 0.7
| CHD | 59.6 | 35.8 | 4.6
| GIH | 49.5 | 40.6 | 9.9
| LWK | 18.2 | 54.5 | 27.3
| MEX | 22.8 | 56.1 | 21.1
| MKK | 20.8 | 50.0 | 29.2
| TSI | 28.7 | 50.5 | 20.8
| HapMapRevision=28
}}{{PMID Auto
|PMID=22568453
|Title=Association of CASP3 polymorphism with hematologic toxicity in advanced NSCLC patients treated with platinum-based chemotherapy
}}

{{PMID|17071630}} Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma.

{{PMID|18381704|OA=1
}} Caspase polymorphisms and genetic susceptibility to multiple myeloma.

{{PMID|19938081|OA=1
}} Altered transmission of HOX and apoptotic SNPs identify a potential common pathway for clubfoot.

{{PMID Auto
|PMID=23212337
|Title=Role of CASP-10 gene polymorphisms in cancer susceptibility: a HuGE review and  meta-analysis
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}